Lipitor Lawsuit News: Bernstein Liebhard LLP Notes Growing Number of Type 2 Diabetes Claims in Federal Lipitor Litigation

Share Article

The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin.

Free Case Review
Our Firm continues to hear from Lipitor patients who allegedly developed Type 2 diabetes from their use of this medication. We are not surprised that this has grown into a large litigation.

Lipitor lawsuits ( that claim the popular statin medication caused patients to develop Type 2 diabetes continue to mount in a federal multidistrict litigation underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to a recent article published by Reuters, the number of filings in the proceeding has surged from 56 to nearly 1,000 in the past five months.* (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“Our Firm continues to hear from Lipitor patients who allegedly developed Type 2 diabetes from their use of this medication. We are not surprised that this has grown into a large litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.

Lipitor Diabetes Allegations
According to the Reuters report, the Lipitor diabetes litigation began to grow after the U.S. Food & Drug Administration (FDA) mandated that the manufacturers of statin medications, including Lipitor, update their labels with information regarding their possible association with Type 2 diabetes. The FDA acted after a study published in JAMA: Internal Medicine in January 2012 indicated that women using this class of medications may be at an increased risk of developing the disease.**

According to court documents, all of the Lipitor lawsuits pending in the District of South Carolina claim that Pfizer, Inc. was aware of the potential association between the statin and diabetes before modifying the drug’s label in February 2012, but concealed this information in order to protect its market share. The complaints also maintain that diabetes information added to the Lipitor label in 2012 remains inadequate. The litigation’s first trial is scheduled to begin in July 2015.

Alleged victims of Lipitor and diabetes may be entitled to compensation from Pfizer, Inc. for their injury-related damages. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.

*, Reuters, August 8, 2014
**, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website